PD L1 News and Research

RSS
Combination of PARP inhibitor and immunotherapy results in tumor regression in SCLC mouse models

Combination of PARP inhibitor and immunotherapy results in tumor regression in SCLC mouse models

Drug combinations could become first-line treatment for metastatic kidney cancer

Drug combinations could become first-line treatment for metastatic kidney cancer

Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors

Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors

Novel approach uses small amounts of tissue to quantify PD-L1 expression levels in tumors

Novel approach uses small amounts of tissue to quantify PD-L1 expression levels in tumors

Immunotherapy may be better than chemotherapy for Merkel cell carcinoma

Immunotherapy may be better than chemotherapy for Merkel cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

New potential immunotherapy target in pancreatic cancer identified

New potential immunotherapy target in pancreatic cancer identified

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

International study increases group of lung cancer patients who may benefit from immunotherapy

International study increases group of lung cancer patients who may benefit from immunotherapy

Study reveals unknown mechanism that protects tumor cells from NK cell-mediated cytotoxicity

Study reveals unknown mechanism that protects tumor cells from NK cell-mediated cytotoxicity

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

First-of-its-kind study to test a personalized vaccine in cancer patient

First-of-its-kind study to test a personalized vaccine in cancer patient

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

HalioDx announces availability of Brightplex, a high capacity IHC multiplex technology

New project identifies immune checkpoint inhibition as potential treatment for angiosarcomas

New project identifies immune checkpoint inhibition as potential treatment for angiosarcomas

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.